We’re all familiar with mutations in DNA driving disease, and with the ever growing progress in using genome engineering methods such as CRISPR/Cas9 as therapeutic to repair such damage and offer real cures. However, our transcriptomes undergo an enormous amount of natural editing in their life cycles. Join us in this ELRIG networking session to explore how these editing events can lead to disease and some of the ideas about how we can manipulate these processes for research and therapeutics and how will we take it to the clinic.
University of Cambridge
Patent Attorney Candidate
ip2 Intellectual Property Partners
Chief Scientific Officer
STORM Therapeutics Limited